Confidential — Internal Planning Document
$5M Capital Deployment Plan — December 2026
Vital Guard Pharma (VGP) + USA Medical Surplus (UMS) · Full $5M deployed in one month
$5,000,000
Monthly Capital Pool
$250K/day
Deployment Pace (20-day mo)
65 / 25 / 10
VGP / UMS / Shared Split
$65K/mo
Loan Payment — Covered Today
⏱ DEADLINE: NOVEMBER 14, 2026 · LAUNCH: DECEMBER 2026
Operating Principle — Full $5M in One Month
The entire $5M is deployed in December 2026. Every dollar has an owner, a category, and a purpose. Do not treat any portion as idle reserve. Capital is deployed into inventory, sourcing, receivables, and fulfillment — collections return to the pool and are redeployed again. The goal is to run $5M through the system every single month, not to spend it once and wait.
"Got to remember that we're gonna pay $65K a month on that — so it's gonna be most likely divided between all of our different sources of product and sales. I need that to be written out and predicted based on where we're currently at. That can be sourcing from Canada, sourcing from the secondary market, purchasing from manufacturers for controlled substances, and so on."
🔊 Austin H., CEO · Voice Note · Sep 28, 2026
1 · Exact $5M Monthly Allocation
This is the starting allocation. Management should rebalance weekly based on sell-through, gross profit dollars, days-to-cash, and compliance capacity — not instinct.
| Entity / Use |
Monthly |
% |
Scale |
Rule |
| VGP Vital Guard Pharma — $3,250,000 (65%) |
Non-controlled Rx inventory |
$1,350,000 |
27% |
|
Core high-turn pharmacy inventory; favor repeat demand and short cash cycles. |
Cold-chain / specialty / insulin / injectables |
$650,000 |
13% |
|
Use for products with validated storage/handling capability and reliable pharmacy demand. |
Controlled inventory |
$550,000 |
11% |
|
⚠️ Only after all applicable DEA/state permissions, security, suspicious-order controls, and customer validation are active. |
Pharmacy A/R bridge |
$450,000 |
9% |
|
Supports rapid shipping while collections are outstanding; target shortest possible collection cycle. |
Opportunistic high-demand inventory |
$250,000 |
5% |
|
Shortage-driven, high-turn or high-margin buys with pre-identified demand. |
| VGP Subtotal |
$3,250,000 |
65% |
| |
| UMS USA Medical Surplus — $1,250,000 (25%) |
Domestic reseller / device purchasing |
$500,000 |
10% |
|
Fast-turn diabetic devices and compliant surplus channels; strict inspection and traceability. |
Canadian sourcing |
$400,000 |
8% |
|
⚠️ Only through legally authorized channels/products. Never assume NABP status itself authorizes importation. |
OTC / Rx devices / diabetic products |
$200,000 |
4% |
|
Mail-in, street, reseller and wholesale device purchasing with defined exit buyers. |
Freight / receiving / QA / returns |
$150,000 |
3% |
|
Inbound logistics, testing/inspection, reconciliation, deductions and returns management. |
| UMS Subtotal |
$1,250,000 |
25% |
| |
| Shared Combined Operations — $500,000 (10%) |
Sales / cold calling / data / CRM |
$150,000 |
3% |
|
Lead lists, calling capacity, customer acquisition, account management and data quality. |
Warehouse / fulfillment capacity |
$150,000 |
3% |
|
Labor, packing, cold-chain materials, systems and throughput bottlenecks. |
Compliance / quality / legal |
$100,000 |
2% |
|
Licensure maintenance, audits, QA, contracts, security, and regulatory execution. |
Timing / liquidity bridge |
$100,000 |
2% |
|
Same-week supplier/receivable timing needs; sweep unused balance into approved buys. |
| Shared Subtotal |
$500,000 |
10% |
| |
| TOTAL — Every dollar assigned; no unowned capital |
$5,000,000 |
100% |
Reallocation rule: any category that cannot legally deploy its weekly target must release unused funds to another approved category within 48 hours. |
2 · Monthly Deployment Engine
| Metric | Minimum Standard | What Management Tracks |
|---|
| Daily deployed | $250,000 | POs funded, inventory received, A/R bridged, same-week redeployments |
| Weekly deployment | $1,250,000 | No dept carries unexplained shortfall into the next week |
| Monthly deployment | $5,000,000 | 100% of pool assigned and used in approved business activity |
| Inventory aging | <30 days; target <14 | Aging by SKU, buyer, supplier and entity |
| Collections | Fastest achievable | DSO, overdue balances, stop-ship thresholds |
| Capital turns | 1.0× → build to 1.25–1.5× | Cash-to-cash cycle and same-month redeployment rate |
| Gross profit | Never chase volume alone | GP dollars, margin %, deductions, freight, returns and bad debt |
UMS Live Financials — Baseline
✅ Current net profit already exceeds loan payment. Loan is serviceable before a single dollar is deployed.
December Launch Prerequisite
This plan assumes VGP has required accreditation, state licenses, DEA authority where applicable, cold-chain capability, trained sales staff, and documented lawful sourcing before capital is deployed into the corresponding category.
3 · Vital Guard Pharma — $3.25M Monthly Mandate VGP
Operating Principles
A
Build a repeat-order pharmacy book — Segment accounts by weekly purchasing capacity, product class, payment speed and margin. Sales management should know exactly how much each active account can absorb every week.
B
Buy against demand — Sales team identifies likely buyers before purchasing. Daily demand sheet: SKU, quantity, target customer, expected sell price, required delivery date, margin and licensing status.
C
Separate product lanes — Run separate lanes for non-controlled Rx, controlled substances, cold-chain/specialty, and opportunistic inventory. Each lane gets its own buyer, seller, compliance checklist, aging, and cash-cycle target.
D
Controlled substances remain capacity-limited — Do not make controlled products the default for excess capital. Scale only to the level supported by lawful demand, DEA/state authorization, secure storage, recordkeeping, and suspicious-order monitoring.
E
Make A/R a controlled investment — The $450K A/R bridge is not permission for loose terms. Best limits go to pharmacies with strong history and fast payment. Use stop-ship rules and aging alerts.
F
Cold-chain readiness before volume — Validate storage, packing, temperature control, carrier process, excursion handling and returns before scaling cold-chain inventory.
VGP KPI Targets
| KPI | Target / Management Use |
|---|
| Daily pharmacy sales capacity | Build toward a level that clears weekly purchasing without inventory buildup |
| Repeat-order share | Increase monthly; recurring customers should dominate volume |
| DSO / collection speed | Track by account; fastest-paying customers receive the most capital |
| Inventory aging | Flag at 7 / 14 / 30 days; mandatory action plan for aging inventory |
| Gross profit dollars | Primary economic output, not revenue alone |
| Compliance exceptions | Zero unresolved exceptions before scaling the affected lane |
4 · USA Medical Surplus — $1.25M Monthly Mandate UMS
Operating Principles
A
UMS is the sourcing engine — Focus on purchasing, receiving, inspection, device/surplus opportunities and supplier development. Create reliable inventory flow and pricing advantages for the combined system.
B
Domestic reseller purchasing — Deploy $500K/month only into products with verified condition, traceability and a defined resale path. Scorecards rank suppliers by defect rate, deduction rate, delivery speed and realized margin.
C
Canadian sourcing — Use the $400K bucket only for products and import pathways that compliance confirms are lawful. Accreditation and state licensure do not by themselves create a general right to import Canadian prescription drugs.
D
Device and diabetic-product concentration — $200K/month for repeatable, fast-turn device categories where UMS can source at a meaningful spread and VGP or approved wholesale buyers can absorb consistent volume.
E
Receiving/QA as a profit center — The $150K logistics/QA bucket protects the other $1.1M. Fast check-in, serial/lot capture, condition grading, deductions and immediate routing prevent cash from getting trapped in unresolved inventory.
UMS Active Sourcing Channels
🚐 Dispatch — Local Street
Driver routes acquiring from households and community sellers. Dareth (Lead) + Benson + Marquees.
🇨🇦 Canadian Sourcing
RX and medical devices. $400K/mo. Pathway-specific legal clearance required before funding.
🌐 Nationwide Reseller
King (Nationwide Purchasing Mgr). $499K YTD proven channel.
📬 Mail-In
Gilbert (Mail-in Purchasing). Low overhead, national reach, scalable with volume.
5 · VGP + UMS Capital Flywheel
1
SOURCE
UMS develops domestic/device/authorized international supply; VGP develops manufacturer/authorized drug supply
2
VERIFY
Licensing, trading-partner status, product identity, traceability, condition, lot/serial data and customer eligibility
3
PLACE CAPITAL
Fund only inventory or receivables tied to an approved product lane and accountable owner
4
SELL FAST
VGP focuses pharmacy/clinic/hospital demand; UMS handles permitted wholesale/device channels
5
COLLECT
Collections management is part of sales. Cash is not considered realized until received
6
REDEPLOY
Collected cash returned to purchasing immediately — increasing turns without requiring another loan
Intercompany control: transfers or sales between VGP and UMS must be documented with proper invoices, inventory ownership, pricing policy, tax/accounting treatment and regulatory responsibility. The entities can operate synergistically without blurring legal ownership or compliance accountability.
6 · December Launch Sequence + Management Controls
| Timing | Required Actions |
|---|
| Before Dec 1 | Finalize lending close, bank controls, authorized signers, entity budgets, accreditation/licensing status, DEA permissions, sourcing approvals, supplier lists, pharmacy credit limits and weekly reporting. |
| Week 1 | Deploy first $1.25M into already-approved high-turn inventory and existing demand. Do not use Week 1 to experiment with unproven categories. |
| Week 2 | Deploy next $1.25M plus redeployed collections. Kill bottlenecks in receiving, shipping, collections and purchasing approvals. |
| Week 3 | Shift money toward categories with highest realized gross profit per day of capital employed. Reduce slow lanes. |
| Week 4 | Reach full $5M monthly deployment, close aging inventory, collect receivables, and publish the next month's capital map before month-end. |
| End of Month | Close aging inventory, collect outstanding receivables, publish the January capital map before Dec 31 — same $5M redeploys on Jan 1. |
Daily Management Dashboard
Capital deployed today
$ ___________
Month-to-date deployed
$ ___ / $5.0M
Cash collected today
$ ___________
Inventory received / shipped
$ ___ / $ ___
A/R outstanding + DSO
$ ___ / __ days
Inventory >7 / >14 / >30 days
$ / $ / $
Gross profit booked
$ ___ and __ %
Unresolved compliance exceptions
# ___________
Available capital for tomorrow
$ ___________
Non-negotiable: Full deployment is not the same as reckless deployment. If demand, compliance, storage, customer eligibility, or collection controls are not ready, reallocate to another approved lane rather than forcing inventory into a category that cannot safely turn.
7 · Regulatory Guardrails
🏛️
NABP Drug Distributor Accreditation
Designed for businesses that store, handle and ship prescription drugs/devices. Includes licensure, facility, recordkeeping, authentication/verification criteria. Treat as one layer of the compliance stack — not a blanket authorization for every product or jurisdiction.
📋
Wholesale Licensure / Authorized Trading Partners
FDA states prescription drugs should be purchased from wholesale drug distributors with valid U.S. licenses and lawful authorization. Build supplier verification into purchasing approval.
🇨🇦
Canadian Sourcing — FDA Framework
FDA has a specific statutory/regulatory framework for importation of certain prescription drugs from Canada. Any Canadian program must be product- and pathway-specific and legally cleared before funds are committed.
🔒
Controlled Substances — DEA Requirements
DEA requirements include registration, recordkeeping, security/diversion controls and suspicious-order obligations for distributors. Controlled-inventory growth should never outpace the company's compliance system.
Management Conclusion
December objective: establish a repeatable system capable of putting $5M to work every month without recreating a cash-flow problem. The combined system should be measured by capital turns, realized gross profit, collection speed, inventory aging, supplier reliability and compliance quality. Once those numbers are stable, the same $5M can support materially more than $5M of monthly purchase throughput through redeployment.